About the Company
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SCYX News
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024Data analysis for the FURI ...
SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023
SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share but beat on revenue for the fourth ...
Scynexis files patent for treatment of fungal infections with enfumafungin derivative triterpenoids
Discover Scynexis Inc.'s patent for enfumafungin derivative triterpenoid antifungal compounds targeting fungal infections in low pH environments. Learn about the innovative treatment options for yeast ...
Buy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial Results
Analyst Michael Higgins of Ladenburg Thalmann & Co. maintained a Buy rating on Astria Therapeutics (ATXS – Research Report), with a ...
NRx unveils plan to battle naked short selling in shares
NRx Pharmaceuticals (NRXP) stock jumped 9% in premarket trading Tuesday after the company unveiled a plan to combat naked ...
Loading the latest forecasts...